Alnylam Pharmaceuticals (ALNY) Net Margin Growth (3y) (2012 - 2026)

Alnylam Pharmaceuticals (ALNY) Net Margin Growth (3y) (2012 - 2026) Analysis & Trends

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Net Margin Growth (3y) (Qtr)
1 Oculis Holding AG 68,785.72 Bn 68,785.72 Bn - -
2 Nanobiotix 1,895.57 Bn 1,895.51 Bn - -
3 BeOne Medicines 471.35 Bn 466.56 Bn 1.35 Bn 9,283.00
4 NuCana 279.75 Bn 279.75 Bn - -
5 Vertex Pharmaceuticals 120.24 Bn 113.00 Bn 2.59 Bn 506.00
6 Regeneron Pharmaceuticals 67.80 Bn 59.04 Bn 3.31 Bn -569.00
7 Belite Bio 62.51 Bn 62.51 Bn - -
8 Argenx Se 57.38 Bn 57.38 Bn 1.41 Bn 6,537.00
9 Revolution Medicines 37.78 Bn 37.78 Bn - -
10 Alnylam Pharmaceuticals 35.71 Bn 32.70 Bn 959.66 Mn 7,218.00

Historic Data

Download Data
DateValue
Mar 31, 2026 7,218.00
Dec 31, 2025 7,210.00
Sep 30, 2025 17,701.00
Jun 30, 2025 11,482.00
Mar 31, 2025 10,963.00
Dec 31, 2024 8,585.00
Sep 30, 2024 8,672.00
Jun 30, 2024 8,339.00
Mar 31, 2024 9,946.00
Dec 31, 2023 11,754.00
Sep 30, 2023 22,095.00
Jun 30, 2023 8,580.00
Mar 31, 2023 12,865.00
Dec 31, 2022 32,337.00
Sep 30, 2022 14,407.00
Jun 30, 2022 36,747.00
Mar 31, 2022 43,369.00
Dec 31, 2021 90,531.00
Sep 30, 2021 1.17 Mn
Jun 30, 2021 46,095.00